Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two small molecule drugs, fluorouracil and metronidazole. Fluorouracil is an antimetabolite and pyrimidine analog that inhibits DNA synthesis by blocking thymidylate synthetase, leading to impaired cell division and cancer cell death. Metronidazole is a nitroimidazole antibiotic with antibacterial and antiparasitic activity; it also inhibits the metabolism of fluorouracil, increasing its blood levels. The combination has been investigated for use in metastatic colorectal cancer but was found to significantly increase the toxicity of fluorouracil without improving efficacy due to reduced clearance of fluorouracil when administered with metronidazole[1][3][5]. This combination should generally be avoided except under special circumstances due to the risk of enhanced toxicity[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluorouracil + metronidazole.